Keryx Biopharmaceuticals (KERX) 10-Q2008 Q1 Quarterly report

Filed: 12 May 08, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: AA, acetate, acute, affidavit, aluminum, amd, Amgen, animal, avoid, BF, bid, Biotech, bleeding, burn, calcium, calendar, canine, carbonate, citrate, classification, combination, commerical, committed, consecutive, conserve, contesting, corroborated, deteriorate, deteriorated, director, discontinue, discount, discounted, District, Dutch, enjoin, expended, expert, export, ferric, Fosrenol, FSP, gastrointestinal, Genzyme, Global, hierarchy, hydrochloride, illiquidity, ImClone, improperly, indirectly, inhibiting, inhibitor, intention, interfering, jeopardize, lanthanum, large, LLC, loan, magnesium, match, mechanism, member, methodology, Millennium, minimum, mTOR, mutual, NASDAQ, negotiation, notification, notified, Oliviero, Onyx, OSI, Overview, Panion, par, paragraph, pathway, payable, PhosLo, plc, prompted, quantity, quoted, readily, recoup, regain, reliability, reliable, Renagal, Renvela, restoration, rollover, secondary, sevelamer, shareholder, Shire, Shortly, Southern, SPL, stabilize, standard, student, sublicense, submission, sued, supple, Taiwan, testimonial, tort, transfer, undertaken, uneven, unobservable, unsuccessful, Vertex, voluntary, workforce, workout, write, Wyeth, York

Removed: accelerated, accurate, ADI, aggregate, alleging, allocated, anniversary, area, arose, assert, assumption, authorization, Bankr, Bankruptcy, cancelled, CAO, careful, case, Chapter, comparative, confirm, confirmatory, Counsel, deliver, depending, depreciate, derive, detection, Encouragement, endpoint, Enterprise, equal, escrow, established, examination, exercised, expired, failed, FIN, forma, forward, funded, heparin, heparinoid, highlighting, hope, ii, iii, immaterial, importance, incidental, indefinite, Inducement, intrinsic, jurisdiction, killed, macroalbuminuria, marker, marketable, matter, microalbuminuria, Ministry, modestly, move, mucosa, nonvested, overt, partially, pilot, porcine, premium, prepare, pro, projecting, proposed, purporting, quantitative, RDD, ready, realizing, recognizing, regression, released, repaid, represented, representing, reproduce, secure, senior, sensitive, settled, single, sooner, SPA, stream, subpart, SulonexTM, summary, supply, supportive, surrendered, surrogate, thirty, threshold, track, unaware, underpayment, unissued, utilization, utilize, validation, withdraw, withholding, world

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

KERX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

STATEMENT OF CHIEF FINANCIAL OFFICER OF

KERYX BIOPHARMACEUTICALS, INC.

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Keryx Biopharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2008 as filed with the Securities and Exchange Commission (the “Report”), I, James F. Oliviero, Vice President, Finance, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:

1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 12, 2008		/s/ James F. Oliviero
		James F. Oliviero Vice President, Finance Principal Financial and Accounting Officer